New Drug Approvals

Home » Posts tagged 'us'

Tag Archives: us

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Blog Stats

  • 4,809,089 hits

Flag and hits

Flag Counter

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
Follow New Drug Approvals on WordPress.com

Archives

Categories

Recent Posts

Flag Counter

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

Verified Services

View Full Profile →

Archives

Categories

Flag Counter

Daiichi partners with AZ to sell Movantik in US…….Pharmatimes, Selina McKee


Naloxegol.svg
Naloxegol
Daiichi partners with AZ to sell Movantik in US 
March 19, 2015

Selina McKee

News editor, Selina McKee

Selina McKee

Qualified from King’s College London with BSc (hons) in Human Biology in 1999 with an interest in medical journalism. Has since held positions as a database analyst managing a portfolio of companies at Evaluate Pharma, and as news editor at Pharma Marketletter. Fluent German speaker, interests include music, piano, reading, astronomy, photography and Formula 1.

Daiichi partners with AZ to sell Movantik in US

AstraZeneca has chosen Daiichi Sankyo to help sell its novel constipation drug Movantik (naloxegol) in the US, as the firm gears up for its launch in April.

First-in-class Movantik was cleared in the US last September for the treatment of opioid-induced constipation in adults with chronic non-cancer pain, for which there is still significant unmet need.

PharmaTimes Magazine and Digital offer a unique blend of news stories, interviews, features, case studies, analysis and comment on the critical issues facing the pharma and healthcare sectors. Our wide editorial lens combined with our editorial philosophy to deliver sharp, informed and entertaining coverage from the perspective of the industry, the payer and the patient, allows PharmaTimes to help kickstart conversations that matter most to our audience of decision makers within pharma and the healthcare profession.PharmaTimes Competitions are a critical facet of our business, providing a unique opportunity for industry to showcase its most talented people in marketing, communications, sales and clinical research. No other competitions offer entrants the chance to compete head-to-head in real-life challenges devised by independent industry and healthcare experts, to test their skill sets against their peers in real time, and receive feedback to ensure the whole experience is a valuable learning process.

 Selina McKee

Selina McKee

Editor, UK News at PharmaTimes

London, United Kingdom
Pharmaceuticals
uk.linkedin.com/pub/selina-mckee/4/174/339/en

Experience

Editor, UK News

PharmaTimes

September 2005 – Present (9 years plus

Company News Editor

Pharma Marketletter

November 2003 – August 2005 (1 year 10 months)

Research Analyst

Evaluate Pharma

March 2000 – January 2003 (2 years 11 months)

Education

King’s College London, U. of London

BSc (Hons) Human Biology

1996 – 1999

PharmaTimes Media Ltd.
8-10 Dryden Street
Covent Garden
London WC2E 9NA

Email: pharma@pharmatimes.com
Telephone: +44 (0)20 7240 6999
Fax: +44 (0)20 7240 4479

Company Registration Number: 09019637

Selina McKee

Map of Dryden St, London WC2E 9NA, UK
Dryden St London WC2E 9NA, UK

Registered in England & Wales at:
PharmaTimes Media Limited
8-10 Dryden Street
Covent Garden
London WC2E 9NA

more………….

LINKEDIN

uk.linkedin.com/pub/selina-mckee/4/174/339/en

Authors – PharmaTimes

Selina McKee. Qualified from King’s College London with BSc (hons) in Human Biology in 1999 with an interest in medical journalism. Has since held positions .

Selina McKee (@PTSelinaMcKee) | Twitter

The latest Tweets from Selina McKee (@PTSelinaMcKee). News Editor for http://t.co/o6l54nzsxb & PharmaTimes Magazine. Also on your mobile. Sussex, UK.

5 Dryden Street, Covent Garden, London. London – , Greater London, WC2

Covent Garden Interior May 2006

covent garden. 2 Dryden Street. London

Dryden Street, London
.
Happy Hands provides domestic cleaning in Covent Garden (WC2) and other districts in London.

US Orphan Drug Market Outlook 2018 ……….download available


 

US Orphan Drug Market Outlook 2018
Academia.edu

󰁕󰁓 󰁏󰁲󰁰󰁨󰁡󰁮 󰁄󰁲󰁵󰁧 󰁍󰁡󰁲󰁫󰁥󰁴 󰁏󰁵󰁴󰁬󰁯󰁯󰁫 󰀲󰀰󰀱󰀸 󰂩󰁋󰁵󰁩󰁣󰁋 󰁒󰁥󰁳󰁥󰁡󰁲󰁣󰁨
US Orphan Drug Pipeline Insight by Phase & Indication 5.1 Research 5.2 Preclinical 5.3 Phase I 5.4 Phase I/II 5.5 Phase II 5.6 Phase II/III 5.7 Phase III …

http://www.academia.edu/7453102/US_Orphan_Drug_Market_Outlook_2018 …………… download at this site

Market Overview

In the largest market for orphan drugs, USA, there was a shortage of adequate therapies for treating many rare diseases. These therapies were not developed as companies did not expect these drugs to be highly profitable. Hence there was a lack of interest and thus investment on the part of pharma companies in the USA. Therefore, the FDA introduced incentives for developing such drugs. This step taken by the FDA was successful in creating a thriving market for orphan drugs. It was in the USA first that a special law exclusively for governing orphan drugs was framed in the form of the Orphan Drug Act of 1983. This led to an increase in the popularity of orphan drugs. The FDA also has been continuously increasing its efforts to support this market by providing significant financial and non-financial incentives to the pharmaceutical companies to attract them. This has been one of the major drivers of growth for the US orphan drugs market.

Figure 3-1: US Orphan Drug Market (US$ Billion), 2012-2018

2012201320142015201620172018

Source: KuicK Research

see my profile

http://ictmumbai.academia.edu/AnthonyMelvinCrastoPhD

The future of orphan drugs - drugdiscovery.com